Results 101 to 110 of about 2,590,210 (272)

Microwave Ablation Combined With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non‐Small Cell Lung Cancer—Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 1, January 2026.
Microwave Ablation Plus Chemotherapy versus Chemotherapy Alone in Advanced NSCLC. ABSTRACT Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer‐related mortality worldwide. Although chemotherapy remains a cornerstone in the treatment of advanced NSCLC, local ablative strategies such as microwave ablation (MWA) have emerged as ...
Paul C. Onyeji, Amrinder Kaur, Leo Consoli, Shivank Dani, Sonise Momplaisir‐Onyeji, Felipe S. Passos, Torsten Doenst, Hristo Kirov, Tulio Caldonazo   +8 more
wiley   +1 more source

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Indian Journal of Anaesthesia, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide.
S. Solanki, S. Mukherjee, V. Agarwal, R. Thota, Kalpana Balakrishnan, S. Shah, Neha Desai, R. Garg, R. Ambulkar, N. Bhorkar, Viplab Patro, S. Sinukumar, Meenakshi V Venketeswaran, Malini Joshi, R. H. Chikkalingegowda, V. Gottumukkala, P. Owusu-Agyemang, A. Saklani, S. Mehta, R. Seshadri, J. Bell, S. Bhatnagar, J. Divatia   +22 more
semanticscholar   +1 more source

Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Mirvetuximab soravtansine (MIRV) is an antibody‐drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)‐targeting antibody via the cleavable sulfo‐SPDB linker. MIRV targets and binds to FRα with high affinity and specificity, releasing the DM4 payload intracellularly following MIRV‐FRα complex internalization ...
Rajeev Menon, Emarjola Bako, Shuhan Liu, James Stec, Sheetal Thakur, Emily Deutschman, Olga Ab, Shweta Jain   +7 more
wiley   +1 more source

Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

BJS Open, 2019
Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) aims to achieve macroscopic tumour resection combined with HIPEC to destroy microscopic disease.
S. Hallam, R. Tyler, M. Price, A. Beggs, H. Youssef   +4 more
semanticscholar   +1 more source

11C‐Hydroxyephedrine PET/CT for preoperative surgical planning in large pheochromocytoma and paraganglioma

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Early detection of metastases and timely surgical intervention play a crucial role in the management of neuroendocrine tumors. In large‐sized pheochromocytomas and sympathetic paragangliomas (PPGL), functional imaging with positron emission tomography (PET) is recommended, as it improves the detection of metastases, which may go undetected on ...
Achyut Ram Vyakaranam, Olov Norlén, Alina Akural, Joakim Crona, Matilda Annebäck, Branislav Klimàcek, Peter Stålberg, Anders Sundin, Tobias Åkerström   +8 more
wiley   +1 more source

Impact of extent of disease on 1-year healthcare costs in patients who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: retrospective observational cohort study [PDF]

, 2020
Bob J. L. Kooijman, Judith E. K. R. Hentzen, Christian S. van der Hilst, Lukas B. Been, Robert J. van Ginkel, Patrick Hemmer, Joost M. Klaase, Schelto Kruijff   +7 more
openalex   +1 more source

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy

International Journal of Gynecological Cancer, 2019
Objective In previous studies, neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary cytoreductive surgery as initial treatment for advanced epithelial ovarian cancer. Our study aimed to compare surgical and survival
Y. Lyons, H. Reyes, M. Mcdonald, A. Newtson, E. Devor, D. Bender, M. Goodheart, J. Gonzalez Bosquet   +7 more
semanticscholar   +1 more source

Risk Factors of Causing Acute Kidney Injury after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Using Cisplatin

, 2022
Toshiyuki Kitai, Kazuyuki Okada, Hidekazu Takagi, Naoki UYAMA   +3 more
openalex   +2 more sources

Factors influencing long‐term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms

BJS Open, 2019
Pseudomyxoma peritonei (PMP) is a rare disease, most commonly of appendiceal origin. Treatment consists of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS–HIPEC).
W. J. Eden, Niels F. M. Kok, P. Snaebjornsson, Katarzyna Jóźwiak, K. Woensdregt, P. Bottenberg, Henk Boot, A. Aalbers   +7 more
semanticscholar   +1 more source

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An, Rutie Yin, Li Wang, Bairong Xia, Qi Zhou, Hongying Yang, Jianqing Zhu, Kui Jiang, Zhengzheng Chen, Qiang Wu, Wei Duan, Yi Huang, Hui Zhang, Shuqing Wei, Guiling Li, Yuanguang Meng, Ke Wang, Xinfeng Yang, Xianghua Huang, Lingya Pan, Jinjin Yu, Ge Lou, Yu Zhang, Huaijun Zhou, Xiaoqing Guo, Hong Yang, Xiaodong Cheng, Xiumin Li, Wuliang Wang, Hongqin Zhao, Yunxia Li, Yingjie Yang, An Lin, Wenjun Cheng, Lihong Chen, Xiaoying Xie, Wen Di, Yuanjing Hu, Mo Chen, Hongwu Wen, Liping Cai, Xiaohua Wu, Zhongqiu Lin, Quanren Wang, Xinfeng Yang, Ning Li   +56 more
wiley   +1 more source